Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study
Abstract Background To evaluate 5-year outcomes of anti-vascular endothelial growth factor (VEGF) monotherapy and combination therapy of anti-VEGF agents and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) in a real-world Chinese population. Methods Retrospective study. Fifty-...
Main Authors: | Jingyuan Yang, Mingzhen Yuan, Erqian Wang, Song Xia, Youxin Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | BMC Ophthalmology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12886-019-1245-4 |
Similar Items
-
Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy
by: Mümin Hocaoğlu, et al.
Published: (2016-01-01) -
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
by: Xiaoya Gu, et al.
Published: (2019-07-01) -
Polypoidal Choroidal Vasculopathy Associated with Optic Disc Coloboma
by: Yumiko Nakano, et al.
Published: (2018-01-01) -
Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
by: Zeynep Alkin, et al.
Published: (2016-12-01) -
AFLIBERCEPT IN TREATMENT OF RESISTANT POLYPOID CHOROIDAL VASCULOPATHY: SHORT-TERM RESULTS
by: E. K. Pedanova, et al.
Published: (2017-12-01)